Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era

CMAJ. 2021 Apr 12;193(15):E523. doi: 10.1503/cmaj.78240.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use*
  • COVID-19 / epidemiology
  • Canada / epidemiology
  • Humans
  • Infant
  • Palivizumab / therapeutic use*
  • Pandemics
  • Practice Guidelines as Topic
  • Respiratory Syncytial Virus Infections / prevention & control*
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Palivizumab